| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1184 | 2020 |
| LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis D Melisi, S Ishiyama, GM Sclabas, JB Fleming, Q Xia, G Tortora, ... Molecular cancer therapeutics 7 (4), 829-840, 2008 | 365 | 2008 |
| Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer D Melisi, R Garcia-Carbonero, T Macarulla, D Pezet, G Deplanque, ... British journal of cancer 119 (10), 1208-1214, 2018 | 231 | 2018 |
| Key cancer cell signal transduction pathways as therapeutic targets R Bianco, D Melisi, F Ciardiello, G Tortora European journal of cancer 42 (3), 290-294, 2006 | 213 | 2006 |
| Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ... Oncotarget 5 (9), 2839, 2014 | 209 | 2014 |
| Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative … G Tortora, R Caputo, V Damiano, D Melisi, R Bianco, G Fontanini, ... Clinical Cancer Research 9 (4), 1566-1572, 2003 | 197 | 2003 |
| Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib IM Silverman, A Hollebecque, L Friboulet, S Owens, RC Newton, H Zhen, ... Cancer discovery 11 (2), 326-339, 2021 | 183 | 2021 |
| Modulation of pancreatic cancer chemoresistance by inhibition of TAK1 D Melisi, Q Xia, G Paradiso, J Ling, T Moccia, C Carbone, A Budillon, ... Journal of the National Cancer Institute 103 (15), 1190-1204, 2011 | 179 | 2011 |
| Angiopoietin-like proteins in angiogenesis, inflammation and cancer C Carbone, G Piro, V Merz, F Simionato, R Santoro, C Zecchetto, ... International journal of molecular sciences 19 (2), 431, 2018 | 178 | 2018 |
| Vascular endothelial growth factor receptor-1 contributes to resistance to anti–epidermal growth factor receptor drugs in human cancer cells R Bianco, R Rosa, V Damiano, G Daniele, T Gelardi, S Garofalo, V Tarallo, ... Clinical Cancer Research 14 (16), 5069-5080, 2008 | 178 | 2008 |
| EMT and treatment resistance in pancreatic cancer N Gaianigo, D Melisi, C Carbone Cancers 9 (9), 122, 2017 | 147 | 2017 |
| FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements TS Bekaii-Saab, JW Valle, E Van Cutsem, L Rimassa, J Furuse, T Ioka, ... Future Oncology 16 (30), 2385-2399, 2020 | 126 | 2020 |
| NF-κB as a target for pancreatic cancer therapy C Carbone, D Melisi Expert opinion on therapeutic targets 16 (sup2), S1-S10, 2012 | 123 | 2012 |
| HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ... International journal of cancer 139 (12), 2859-2864, 2016 | 119 | 2016 |
| NF-κB as a target for cancer therapy D Melisi, PJ Chiao Expert opinion on therapeutic targets 11 (2), 133-144, 2007 | 118 | 2007 |
| Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma L Maggino, G Malleo, G Marchegiani, E Viviani, C Nessi, D Ciprani, ... JAMA surgery 154 (10), 932-942, 2019 | 113 | 2019 |
| IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-κB activation Z Zhuang, HQ Ju, M Aguilar, T Gocho, H Li, T Iida, H Lee, X Fan, H Zhou, ... Clinical Cancer Research 22 (6), 1432-1444, 2016 | 113 | 2016 |
| Secreted interleukin-1α induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-κB D Melisi, J Niu, Z Chang, Q Xia, B Peng, S Ishiyama, DB Evans, PJ Chiao Molecular Cancer Research 7 (5), 624-633, 2009 | 112 | 2009 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, ... The Lancet 402 (10408), 1133-1146, 2023 | 110 | 2023 |
| Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer D Melisi, DY Oh, A Hollebecque, E Calvo, A Varghese, E Borazanci, ... Journal for immunotherapy of cancer 9 (3), 2021 | 110 | 2021 |
